Rader Daniel J
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Am J Cardiol. 2002 Oct 17;90(8A):62i-70i. doi: 10.1016/s0002-9149(02)02635-8.
High-density lipoproteins (HDLs) are strongly related to risk of atherosclerotic cardiovascular disease. Low levels of HDL cholesterol are a major cardiovascular risk factor, and overexpression of the major HDL protein, apolipoprotein (apo) A-I, markedly inhibits progression and even induces regression of atherosclerosis in animal models. Clinical data regarding the effect of increasing HDL cholesterol on vascular events are limited. HDL remains an important potential target for therapeutic intervention. A variety of gene products are involved in the regulation of HDL metabolism. Yet, the mechanisms by which HDL inhibits atherosclerosis are not yet fully understood. There remains much to be learned about HDL metabolism and its relation to atherosclerosis and other cardiovascular risk factors.
高密度脂蛋白(HDL)与动脉粥样硬化性心血管疾病风险密切相关。HDL胆固醇水平低是主要的心血管危险因素,主要HDL蛋白载脂蛋白(apo)A-I的过表达在动物模型中可显著抑制动脉粥样硬化进展,甚至促使其消退。关于提高HDL胆固醇对血管事件影响的临床数据有限。HDL仍是治疗干预的重要潜在靶点。多种基因产物参与HDL代谢的调节。然而,HDL抑制动脉粥样硬化的机制尚未完全明确。关于HDL代谢及其与动脉粥样硬化和其他心血管危险因素的关系,仍有许多有待了解之处。